We have previously reported in a series of reports that a Kunitz-type protease inhibitor, bikunin derived from human urine (also known as urinary trypsin inhibitor), suppresses expression of uPA, phosphorylation of ERK1/2, and cancer cell invasion in vitro and peritoneal disseminated metastasis and lung metastasis in vivo (1-5). More recently, we investigated the effects of soybean trypsin inhibitor on the uPA expression, signal transduction involved in the expression of uPA, and invasion in human ovarian cancer HRA cells (6, 7). Soybean trypsin inhibitor contains a Kunitz trypsin inhibitor (KTI) 1 and a Bowman-Birk inhibitor (BBI) (8). We previously showed (6, 7) that 1) uPA expression observed in HRA cells is inhibited by preincubation of the cells with KTI with an IC 50 of ϳ2 M, whereas BBI failed to repress uPA expression; 2) cell invasiveness is inhibited by treatment of the cells with KTI with an IC 50 of ϳ3 M, whereas BBI failed to suppress cell invasion; 3) KTI suppresses HRA cell invasion by blocking uPA up-regulation, which may be mediated by one or more binding proteins other than a bikunin-binding protein and/or its receptor; and 4) TGF-␤1-mediated activation of ERK1/2 is significantly reduced by preincubation of the cells with KTI. We conclude that KTI, but not BBI, could inhibit cell invasiveness at least through suppression of the MAPK-dependent uPA signaling cascade (6, 7).
We have previously reported in a series of reports that a Kunitz-type protease inhibitor, bikunin derived from human urine (also known as urinary trypsin inhibitor), suppresses expression of uPA, phosphorylation of ERK1/2, and cancer cell invasion in vitro and peritoneal disseminated metastasis and lung metastasis in vivo (1) (2) (3) (4) (5) . More recently, we investigated the effects of soybean trypsin inhibitor on the uPA expression, signal transduction involved in the expression of uPA, and invasion in human ovarian cancer HRA cells (6, 7) . Soybean trypsin inhibitor contains a Kunitz trypsin inhibitor (KTI) 1 and a Bowman-Birk inhibitor (BBI) (8) . We previously showed (6, 7) that 1) uPA expression observed in HRA cells is inhibited by preincubation of the cells with KTI with an IC 50 of ϳ2 M, whereas BBI failed to repress uPA expression; 2) cell invasiveness is inhibited by treatment of the cells with KTI with an IC 50 of ϳ3 M, whereas BBI failed to suppress cell invasion; 3) KTI suppresses HRA cell invasion by blocking uPA up-regulation, which may be mediated by one or more binding proteins other than a bikunin-binding protein and/or its receptor; and 4) TGF-␤1-mediated activation of ERK1/2 is significantly reduced by preincubation of the cells with KTI. We conclude that KTI, but not BBI, could inhibit cell invasiveness at least through suppression of the MAPK-dependent uPA signaling cascade (6, 7) .
It has been reported that there appeared to be a specific interaction between bikunin and the tumor cell surface (9 -12) . Tumor cells express two types of bikunin-binding proteins; a 40-kDa bikunin-binding protein, which is identical to cartilage link protein, and a 45-kDa bikunin-binding protein, a putative bikunin receptor (12, 13) . Bikunin binds link protein and bikunin receptor on tumor cell surface possibly via the Nterminal Kunitz domain I and the chondroitin sulfate side chain, respectively (13) . Bikunin must bind directly to both of the cell-associated bikunin-binding proteins to suppress expression of uPA and uPA receptor genes (14) . However, KTI has no chondroitin 4-sulfate glycosaminoglycan side chain. Our recent data (6) showed that neither KTI nor BBI inhibits binding of radiolabeled-bikunin to HRA cells or bikunin does not inhibit KTI binding to the cells, suggesting that their binding molecule(s) in the plasma membranes is(are) different from those of bikunin. These data allow us to hypothesize that the mechanisms of KTI will be different from those of bikunin.
These findings lead to many questions about the difference in the mechanisms between KTI and bikunin. We therefore investigated the effects of KTI on the TGF-␤-induced uPA up-regulation and invasiveness of wild-type and transfected cells in relation to the status of Src, ERK, and PI3K/Akt in HRA cells, because TGF-␤1 can stimulate uPA expression through the Src-dependent, ERK-specific signaling cascade (15) . We show for the first time that KTI suppresses uPA up-regulation and promotion of invasion possibly through one or more upstream targets of Src.
EXPERIMENTAL PROCEDURES
Materials-A soybean KTI was obtained from Fuji Oil Co. Ltd., Osaka, Japan (6, 7, 15) . Lipofectamine Plus reagent was purchased from Invitrogen. High molecular weight recombinant uPA and Glu-type plasminogen were obtained from American Diagnostics (Greenwich, CT). Boyden-type cell invasion chambers (BioCoat Matrigel TM invasion chambers) were obtained from Collaborative Biomedical (Franklin Lakes, NJ). Ultrapure natural human TGF-␤1 was from Genzyme (Cambridge, MA) and R&D Systems (Minneapolis, MN). Genistein and PP2 were obtained from Calbiochem. Culture media, penicillin, streptomycin, and fetal bovine serum were purchased from Invitrogen. Tissue culture plastics were purchased from Costar/Corning (Cambridge, MA) and Falcon (BD Biosciences). Bovine serum albumin, Tris-base, dithiothreitol, phenylmethylsulfonyl fluoride, and ammonium persulfate were commercially obtained from Sigma. Acrylamide, bisacrylamide, and polyvinylidene difluoride membrane were from Bio-Rad. X-ray film was purchased from Eastman Kodak Co. ECL was purchased from Amersham Biosciences. Protein estimation reagents (BCA kit) were from Pierce. All other chemicals were of analytical grade.
Pharmacological Inhibitors-The inhibitors were dissolved in Me 2 SO (cell culture grade, Sigma) and used in the following concentrations: wortmannin (100 nM, specific inhibitor of PI3K), LY294002 (10 M, specific inhibitor of the p110 catalytic subunit of PI3K), herbimycin A (35 nM, tyrosine kinase inhibitor), SB202190 (30 M, p38 kinase inhibitor), and PD98059 (50 M, specific inhibitor of MEK). All of the inhibitors except wortmannin (Sigma) were obtained form Calbiochem. The inhibitors diluted in normal growth medium were added to wells containing confluent cells and incubated for 30 min to 1 h. TGF-␤1 (10 ng/ml) was added to serum-free medium containing the respective inhibitors and incubated for the indicated periods of time, after which time the conditioned medium and cells were separately collected, and the cells were counted. The samples were stored at Ϫ80°C until measured. Me 2 SO (0.05%, v/v) diluted in medium was used as a negative control.
Antibodies-The antibodies against uPA (number 3689 (recognizes uPA B-chain) and number 3471 (reacts with uPA A-chain; interferes with binding of uPA to its receptor)) were gifts from Dr. R. Hart (American Diagnostics). Antibodies to human phospho-ERK1/2, phospho-p38 MAPK (Thr 180 /Tyr 82 ), phospho-Akt (Ser 473 ), and total Akt were from New England Biolabs (Beverly, MA). Anti-pan-ERK antibody and anti-phosphotyrosine antibody (clone PY20) were from BD Transduction Laboratories (Lexington, KY). Anti-p38 MAPK antibodies were from Santa Cruz Biotechnology, Inc. Anti-human phospho-Src antibody (Tyr 418 ) was from BIOSOURCE International (Camarillo, CA). Anti-Src (GD11), anti-PI3K p85 subunit, and anti-phosphotyrosine antibody (clone 4G10) were from Upstate Biotechnology, Inc. (Lake Placid, NY). Goat anti-rabbit/mouse IgG horseradish peroxidase-conjugated antibody was from Dako (Copenhagen, Denmark).
Preparation of Oligodeoxynucleotides and Lipofection of HRA CellsAntisense ODNs were selected for sequence target to PI3K p85 (antisense PI3K, 5Ј-GTA CTG GTA CCC CTC AGC ACT CAT-3Ј; sense PI3K, 5Ј-ATG AGT GCT GAG GGG TAC CAG TAC-3Ј) (16) . The corresponding sense ODN was used as control for each antisense ODN. Furthermore, each inverted antisense (iAS) oligonucleotide (iAS c-Src ODN or iAS PI3K ODN) provided additional controls for the vehicle and transfection. The ODNs were synthesized, purified, and modified with phosphorothioate (17) . The constitutively active (CA)-Src plasmid (pUSEamp-Src (Y529F)), wild-type Src plasmid, Myc-tagged CA-Akt plasmid (pUSE-myc-active Akt) (18) , kinase-dead (KD)-Akt plasmid (pUSE-myc-dominant negative Akt), CA-MEK1 plasmid (pUSE-MEK1) (19) , wild-type (WT)-MEK1, or the control vector (pUSE) were obtained from Upstate Biotechnology (www.upstate.com/browse/Search. asp?queryϭAkt and www.upstate.com/browse/Search.asp?queryϭMek) Confluent HRA monolayers were transfected with each plasmid in a pUSE vector according to the manufacturer's instructions. Each well of a 24-well plate was transfected with 250 ng to 2 g of total DNA for 24 h as described previously (20) .
Cell Culture-The ovarian cancer cell line, HRA, was grown in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% (v/v) fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 g/ml) in a 5% CO 2 atmosphere with constant humidity (3). SKOv-3 ovarian cancer cells were obtained from the American Type Culture Collection (Manassas, VA). These cells were maintained in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum and antibiotics. For all experiments in which TGF-␤1 was added, cells were incubated in the serum-free medium. TGF-␤1 (10 ng/ml) was added either alone or in combination in cancer cells preincubated for 30 min to 1 h with inhibitors. The protein concentrations in the supernatants of cell extracts were measured by the Bio-Rad protein assay. Total RNA isolations were done using the TRIzol reagent (Invitrogen).
Preparation of Cell Lysate-The cell monolayers treated with or without various agents for the indicated times were washed with phosphate-buffered saline. 1 ϫ 10 6 cells were lysed in 750 l of lysis buffer containing 20 mM Tris-HCl (pH 7.5), 12.5 mM 2-glycerophosphate, 150 mM NaCl, 1.5 mM MgCl 2 , 2 mM EGTA, 10 mM NaF, 0.5% Triton X-100, 2 mM dithiothreitol, 1 mM sodium vanadate, and 1 mM phenylmethylsulfonyl fluoride at 4°C for 15 min and scraped with a rubber policeman (15) . Cell extracts were then centrifuged at 3000 ϫ g to remove cell debris. All samples were stored at Ϫ70°C until use. In parallel, cells treated in the same condition in different dishes were harvested and counted using a hemocytometer.
Northern Blot Hybridization with cDNA Probes-Northern blot hybridization was carried out as described previously (14, 21) . Samples of total RNA (10 g) were separated by electrophoresis through denaturing 1.2% agarose gels containing 1% formaldehyde and transferred onto nylon or nitrocellulose membranes using standard molecular biological techniques. Hybridization was carried out with [␣-32 P]dCTP by random oligonucleotide priming to specific activities of 0.4 -0.9 ϫ 10 9 cpm/g. uPA cDNA was prepared as described (14, 21) . Filters were reprobed with the cDNA for glyceraldehyde-3-phosphate dehydrogenase to correct for the amount of RNA loaded onto the filters (14, 21) . After hybridization, the membranes were washed and exposed on Kodak BioMax MS-1 film at Ϫ70°C. Filters were quantitated by scanning densitometry using a Bio-Rad model 620 video densitometer with a one-dimensional Analyst software package for Macintosh.
Western Blot Analysis-Each cell was harvested, and cell pellets were lysed as described above. Centrifuged lysates (50 g) from each cell were analyzed by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane by semidry transfer. Membranes were blocked for 1 h at room temperature in Trisbuffered saline containing 0.1% Tween 20 and 2% bovine serum albumin. Blots were probed with the following primary antibodies overnight at 4°C: monoclonal anti-uPA (antibody 3471 plus 3689), anti-␤-actin, anti-phospho-Src, anti-Src, anti-phospho-Akt, ant-Akt, anti-phospho-ERK1/2, or anti-ERK1/2 antibodies. This was followed by incubation with the appropriate horseradish peroxidase-conjugated secondary antibody at a dilution of 1:5000 for 1 h. Detection was achieved by enhanced chemiluminescence (Amersham Biosciences) and exposed to film. Densitometric analysis of Western blots was carried out using the Macintosh Image System (15) .
Extracellular Matrix Invasion Assay-Chemoinvasion assays were carried out in a Boyden chamber as described (22) . The upper surface of chamber was precoated with a layer of artificial basement membrane, Matrigel. The cell suspension (1 ϫ 10 5 cells/well) was added to the upper chamber. The lower chamber was filled with fibroblast-conditioned medium, which acted as a chemoattractant. To measure invasion, incubation was at 37°C for 24 h. The invaded cells in the lower side of the filter were stained with hematoxylin. Triplicate filters were used for each cell type and assay condition, and 10 random fields were counted per filter under a microscope (ϫ400). The experiments of inhibition of cell invasiveness were performed as follows. Because wortmannin is unstable at 37°C in culture medium, it was added every 6 h to the upper chamber of the Matrigel invasion assay.
Statistics-Data are expressed as mean Ϯ S.D. of at least three independent triplicate experiments. All statistical analysis was per-formed using StatView for Macintosh. Statistical analysis was performed by one-way analysis of variance followed by Student's t test. p Ͻ 0.05 was considered statistically significant.
RESULTS

KTI Suppressed TGF-␤1-induced Src Phosphorylation-Pre-
viously, we have investigated signaling pathways involved in TGF-␤1 activation in human ovarian cancer cell lines, HRA and SKOv-3 (15) . We showed that TGF-␤1 induced a marked rise in the level of phosphorylated Src protein in a time-dependent manner (15) . In the present study, we examined whether a soybean KTI suppressed TGF-␤1-induced phosphorylation of Src in HRA and SKOv-3 cells by Western blot. As compared with nonstimulated HRA cells, a 7-fold increase in phosphorylated Src was observed at 20 min in response to 10 ng/ml TGF-␤1 (Fig. 1, lane 1 versus lane 3) . The anti-Src antibodies immunoblotted similar amounts of Src protein in HRA cells, irrespective of whether cells were stimulated with TGF-␤1. Here, we showed that KTI suppressed TGF-␤1-stimulated Src phosphorylation in a dose-dependent manner (lanes 4 -6). Furthermore, KTI also suppressed TGF-␤1 (10 ng/ml, 20 min)-induced phosphorylation of Src in SKOv-3 cells in a dose-dependent manner (lanes 10 -12) .
KTI Suppressed TGF-␤1-induced Phosphorylation of Akt through PI3K-In the previous study (15), we observed concentration-dependent phosphorylation of ERK1/2 and Akt in response to TGF-␤1 beginning with only 0.4 -1 ng/ml TGF-␤1. Src activation has been linked to the activation of MAPK and PI3K in HRA cells (15) . The facts that a MEK inhibitor, PD98059, inhibited the TGF-␤1-induced Akt activation and that PI3K inhibitors, LY294002 and wortmannin, had no effect on the TGF-␤1-induced ERK1/2 activity suggest a presence of crosstalk between the ERK and Akt cascades and that PI3K is a downstream target of MAPK (15) . Here, we show the ability of KTI to TGF-␤1-induced phosphorylation of Akt and ERK1/2 by Western blot using antibodies to phosphorylated Akt (or phosphorylated ERK1/2) or total Akt (or total ERK1/2), respectively.
As shown in Fig. 2A , the increase in Akt phosphorylation in response to TGF-␤1 could be reduced when HRA cells were The role of PI3K in Akt activation was more specifically demonstrated through inhibition with PI3K antisense ODN. We used antisense ODN targeting of the gene for PI3K (lanes 12 and 13) and corresponding control ODNs (S PI3K ODN (lanes 14 and 15) and inverted antisense (iAS) PI3K ODN (data not shown)). PI3K p85 protein expression was reduced by the antisense strategy (15) . Previously, we showed that antisense PI3K ODN transfection abrogated Akt phosphorylation in HRA cells, irrespective of whether cells were stimulated with TGF-␤1 (15) . Note that TGF-␤1-stimulated Akt phosphorylation was not impaired by S PI3K ODN or iAS ODN (15) . In this study, KTI inhibited the TGF-␤1-induced phosphorylation of Akt in the S PI3K ODN cells (lanes 14 and 15) . However, KTI did not affect phospho-Akt level in AS PI3K ODN transfected cells (lanes 12 and 13), because TGF-␤1 could not induce Akt phosphorylation.
To confirm that KTI-dependent suppression of TGF-␤1-stimulated Akt phosphorylation is mediated by ERK, HRA cells expressing CA-MEK1 or control MEK1 were pretreated with KTI, and then stimulated with TGF-␤1. We found that overexpression of CA-MEK1, but not control MEK1, increased basal ERK phosphorylation (Fig. 2C, lane 1 versus lane 4) . KTI could not significantly suppress the TGF-␤1-induced phosphorylation of ERK in HRA cells transfected with CA-MEK1 (Fig. 2C , lane 5 versus lane 6). On the other hand, KTI inhibited the ERK phosphorylation in the control MEK1 cells (Fig. 2C, lane 8  versus lane 9) .
In a parallel experiment, phospho-Akt band was strongly detected in cells expressing CA-MEK1 (Fig. 2E, lanes 4 -6) , but not in cells expressing control MEK1 (Fig. 2E, lanes 7-9) , irrespective of whether cells were stimulated with TGF-␤1. Furthermore, pretreatment for 1 h with 10 M KTI could not significantly diminish the TGF-␤1-induced phosphorylation of Akt band in the CA-MEK1 cells (Fig. 2E, lane 5 versus lane 6) , supporting that KTI may be involved in one or more upstream targets of ERK.
As shown in Fig. 2G , the increase in ERK1/2 phosphorylation in response to TGF-␤1 could be blocked when HRA cells were preincubated with KTI (10 M 14 and 15) .
KTI Suppressed TGF-␤1-stimulated Phosphorylation of ERK1/2 or Akt via an Src-dependent Mechanism-The pharmacological Src inhibitor PP2 inhibited the ERK1/2 (Fig. 3A,  lane 4) and Akt (Fig. 3C, lane 4) activation by 65-75%. KTI did not enhance the suppression by PP2 of TGF-␤1-induced phosphorylation of ERK1/2 (Fig. 3A, lane 5) and Akt (Fig. 3C, lane  5) . functions at the upstream target(s) of Src, the phosphorylation state of ERK1/2 and Akt was examined in cells expressing either wild-type c-Src (WT) or CA-c-Src (Y529F) (Fig. 4) . Immunoblot analysis showed that both cell lines expressed similar amounts of total ERK1/2 and Akt.
Phospho-ERK1/2 bands were strongly detected in the Y529F cells (Fig. 4A, lane 5) , but not in the WT cells (Fig. 4A, lane 1) , even when the cells were not stimulated with TGF-␤1. Furthermore, pretreatment for 1 h with 10 M KTI could not diminish the TGF-␤1-induced phosphorylation of ERK1/2 bands in the Y529F cells (Fig. 4A, lane 8 versus lane 6) , supporting that KTI may be involved in the upstream target(s) of c-Src. In a parallel experiment, CA-c-Src increased basal Akt phosphorylation (Fig. 4C, lane 1 versus lane 5) . KTI could not suppress the TGF-␤1-induced phosphorylation of Akt in HRA cells transfected with CA-c-Src (Fig. 4C, lane 8 lanes 1-7) or constitutively active c-Src (Y529F) (lanes 8 -14) . B and D, values are mean Ϯ S.D. of three experiments. Different letters (a-f) stand for statistical differences (p Ͻ 0.05).
versus lane 6). On the other hand, KTI could inhibit the ERK1/2 and Akt phosphorylation in the WT cells (lane 2 versus lane 4). Effect of KTI on TGF-␤1-induced Expression of uPA mRNA and Protein-Our
uPA protein over ␤-actin protein under control conditions and after administration of TGF-␤1 in the presence or absence of KTI, PP2, PD98059, or LY294002 (Fig. 5C) . We found that TGF-␤1 treatment had a significant effect on expression of the 50-kDa band corresponding to uPA in TGF-␤1-stimulated cells. We verified that the above mentioned changes of the uPA gene expression were associated with changes of uPA protein expression. These data strongly demonstrate suppression by KTI of the upstream targets of Src-MAPK-PI3K signaling cascade, leading to synthesis of uPA mRNA and protein, in response to TGF-␤1 in HRA cells.
Effects of KTI on the TGF-␤1-induced Up-regulation of uPA Expression in Cells Expressing CA-MEK1, Control MEK1, CA-
Akt, or KD-Akt-To further confirm that KTI-dependent suppression of unstimulated and TGF-␤1-stimulated uPA expression is mediated by an upstream target of Src, HRA cells expressing CA-MEK1 or CA-Akt were pretreated with KTI, and then stimulated with TGF-␤1. HRA cells expressing control MEK1 or KD-Akt were used as controls. It has been speculated that if KTI functions at the upstream target(s) of Src, KTI has no ability to inhibit basal uPA expression in cells expressing CA-MEK1 or CA-Akt. We estimated by Western blot the ratio of optical density of uPA protein over ␤-actin protein (Fig. 5C ). Seventy-two hours after transfection, serumdeprived cells pretreated with or without KTI were incubated in the presence or absence of 10 ng/ml TGF-␤ for 24 h, cell lysates were prepared, and then uPA expression was measured by Western blot. 
Effects of KTI on TGF-␤1-stimulated Invasive Response in Cells Expressing Either Wild-type c-Src (WT), CA-c-Src (Y529F), CA-MEK1, Control MEK1, CA-Akt, or KD-Akt-We
reported previously increased cell invasion and elevated uPA production as components of TGF-␤1-induced ovarian cancer cell invasion (15) . TGF-␤1-stimulated HRA cell invasion though modified basement membrane matrix (Matrigel) requires uPA activity (15) . As shown in Fig. 6 , in cells expressing WT-c-Src, TGF-␤1 significantly stimulates cell invasiveness. KTI treatment resulted in suppression of invasion by 40 -50%, irrespective of whether cells were stimulated with TGF-␤1. PD98059 significantly reduced cell invasion by 75%.
In a parallel experiment, the CA-c-Src-transfected cells stimulated with or without TGF-␤1 (10 ng/ml) were analyzed for in vitro invasion (Fig. 7) . CA-c-Src transfection resulted in a 1.5-fold increase in invasiveness. Interestingly, inhibition by KTI did not reduce invasion, whereas treatment of cells with PD98059 markedly suppressed (75%). These data indicate that Src-dependent pathways contribute to an invasive response in HRA cells. CA-c-Src was not impaired by KTI. In agreement with the results of CA-c-Src overexpression, transfection of CA-MEK1 or CA-Akt increased cell invasion ϳ250% relative to empty vector, irrespective of whether cells were stimulated with TGF-␤1, but the increase was not abrogated by pretreatment with KTI. KTI did not suppress invasion in cells express- ing CA-MEK1 or CA-Akt, supporting a role for KTI upstream of Src in the suppression of TGF-␤1-induced uPA expression and invasion. In a parallel experiment, we confirmed that transfection of cells with KD-Akt results in a marked suppression of invasion due to a lack of uPA production.
DISCUSSION
The previous data (15) support a role for TGF-␤1 activation of at least two distinct pathways (Src-MAPK-PI3K-NF-B-dependent and Src-MAPK-AP-1-dependent) for TGF-␤1-dependent uPA up-regulation and promotion of invasion, and that the Src-MAPK-PI3K is a main pathway for this response in HRA cells (Fig. 8) . To examine the KTI-mediated action, we initially tested the effect of pharmacological inhibitors of Src, ERK, and Akt on TGF-␤1-induced uPA expression and invasion. Because pharmacological inhibitors have nonspecific effects that could be misleading, complementary genetic approaches have been performed to confirm the findings from the use of small molecules. For this, we further examined the effect of inhibiting or activating these signaling pathways by transfecting the cells with antisense ODNs to block gene translation/transcription directly through targeting PI3K or with CA-c-Src, CA-MEK1, CA-Akt, or KD-Akt. The treated cells were analyzed for phosphorylation of target proteins as well as uPA expression and invasiveness.
In the present study we have identified a novel mechanism of a soybean KTI regulation in the TGF-␤1 signaling pathways in human ovarian cancer cells. KTI inhibits TGF-␤1-stimulated activation of Src, ERK, and Akt in HRA cells, which results in suppression of uPA expression and invasion. Note that TGF-␤1 stimulates Src kinase, which will activate the MAPK and PI3K/ Akt (15) . The MEK-1 inhibitor PD98059 and PI3K inhibitors wortmannin and LY294002, at concentrations that abolished respective kinase activity, masked the effects of KTI upon uPA production. KTI inhibited the TGF-␤1-induced uPA up-regulation in cells expressing WT c-Src. In cells expressing the CA-cSrc and expressing CA-MEK1 or CA-Akt, however, we found that KTI failed to reverse TGF-␤1-induced activation of ERK and PI3K/Akt as well as TGF-␤1-induced uPA up-regulation and invasion. Thus, complementary genetic approaches confirmed the findings from the use of small molecules. To our knowledge this is the first study to identify an inhibitory action of KTI upon the upstream target(s) of Src in response to TGF-␤1.
Accumulating evidence indicates that activated Src may in- duce cell transformation through Ras-ERK-dependent and Rac1-dependent pathways (23) . Active Src can potently stimulate the Ras-ERK pathway, primarily by the tyrosine phosphorylation of Shc by Src, followed by the recruitment to the membrane of the adapter protein Grb2 and the Ras-guanine nucleotide exchange factor Sos, thereby promoting Ras activation (24) . The Ras-Raf-MEK-ERK and the Ras-PI3K-Akt routes independently or dependently form the two major branches of intracellular signaling. These two pathways have central roles in the regulation of cell survival, proliferation, and invasion. Due to their importance, the cross-talk between these two pathways has been investigated by many investigators (25, 26) . It should be noted that Ras causes the activation of the ERK and PI3K, and PI3K might be upstream/downstream of Ras, thus regulating ERK. Furthermore, PI3K contributes to the activation of phospholipase C-␥. Phospholipase C-␥ causes the mobilization of calcium, which is also required for the activation of ERK. Thus, signals from Src, Ras, PI3K, and phospholipase C-␥ may converge on the activation of ERK. As for TGF-␤ receptor, however, it has been demonstrated that PI3K-Akt, in HRA cells, is a downstream target of ERK. The facts that a MEK inhibitor inhibited the TGF-␤1-induced Akt activation and that PI3K inhibitors had no effect on the TGF-␤1-induced ERK1/2 activation suggests a presence of cross-talk between the ERK and Akt cascades and that PI3K-Akt may be a downstream cascade of ERK. These results allow us to speculate that TGF-␤ receptor may induce Src-Ras through the assembly of the ShcGrb2-Sos complex as well as through other mechanisms (Rac1-dependent pathways), whereas Src-Ras signaling does not directly connect with PI3K-Akt cascade. Our findings are generally consistent with the existence of this linear pathway, but all of the components of the pathway under investigation can be activated by other upstream components that are part of other pathways. Thus, one cannot conclude from these findings that the effects observed are in fact due to a linear pathway.
We sought to identify the site(s) and mechanism(s) responsible for the inhibitory action of KTI. We found that the site of action of KTI is an upstream of Src, at the level of Src itself or above. Inhibition of TGF-␤1-stimulated Src activation by KTI may imply that dephosphorylation at tyrosine of Src or uncoupling of the pathway further upstream is a far more likely mechanism of action. One possibility is a role for an inducible MAPK phosphatase, in particular MAPK phosphatase-1 (27) . We examined whether KTI exposure leads to both the rapid induction of MAPK phosphatase-1 mRNA and its sustained expression. Target genes in ovarian cancer cells were identified by microarray analysis (4). Unfortunately, induction of MAPK phosphatase-1 protein was not seen when cells were treated with bikunin (4) or KTI (data not shown).
TGF-␤ family members signal through transmembrane SerThr kinase receptors that directly regulate the intracellular Smad pathway. Increased levels of Smad3 or Smad4 can induce apoptosis (28) . In the present study, however, TGF-␤1 neither induced apoptosis (data not shown) nor cell growth inhibition in HRA cells. Therefore, the Smad pathway may not be involved in TGF-␤1-dependent signaling cascade in these cell lines. At present we cannot rule out that other signals are also involved. Supporting this possibility is our finding that KTI does not completely suppress the Src-MAPK-PI3K/Akt signaling cascade. If another signal is involved in the inhibitory actions of KTI, then this may explain why KTI is a less effective inhibitor of the Src than pharmacological inhibitor PP2. Alternatively, it may be that other Src-independent mechanisms are also involved and Src only plays a conditional role in the inhibitory effects of KTI. Although the present studies have strongly revealed one such potential mechanism for KTI, involving the upstream target(s) of Src, the cell-specific expression of Src may dictate which effects are manifest upon uPA expression.
KTI is the potent inhibitor of trypsin. KTI inhibited cell invasiveness at least through suppression of MAPK-dependent uPA signaling cascade, whereas Bowman-Birk inhibitor (BBI), another type of soybean trypsin inhibitor, was inactive (6, 7) . Therefore, it is unlikely that trypsin inhibitory activity is specific for suppression of signaling cascades. The specific molecular structure of Kunitz-type protease inhibitor may be important for its action.
There are some conflicting data on biological functions of TGF-␤. TGF-␤ is also a potent inducer of growth inhibition in several cell types, and the TGF-␤ signaling pathway has been implicated in tumor suppression (29) . It has been reported that TGF-␤ inhibited MAPK activity in the rat fibroblast cell line 3Y1 and in v-Src-transformed 3Y0 (SR-3Y1), suggesting that TGF-␤1 specifically induces degradation of activated Src kinase (30) . Additionally, the previous study provides evidence that TGF-␤ in HRA and SKOv-3 cells (15) as well as HaCaT and Madin-Darby canine kidney cells (30) induces a rapid and transient increase in Src kinase activity. On the other hand, TGF-␤ has been reported to negatively regulate Src kinases in HepG2 and PC3 carcinoma cells (30) . Although the reason for the differing results remains unknown, these data are inconsistent with our present results, which may depend on the stage of differentiation, culture conditions, and a cell type.
We have no information whether TGF-␤ can directly induce activation of Src in ovarian cancer cells. We are examining whether Shc will work as an adaptor molecule to mediate phosphotyrosine-dependent signaling events. In fact, several receptor protein-tyrosine kinases have tyrosine autophosphorylation sites, which bind to Shc, and the receptor-bound Shc becomes tyrosine-phosphorylated by the receptor and recruits another Src homology 2-containing adaptor protein to the phosphotyrosine residues. Further studies are therefore warranted to define the role of KTI and each signaling pathway in modulating the sensitivity of ovarian cancer cells to TGF-␤.
In conclusion, using complementary pharmacological and genetic approaches, we have identified a novel mechanism of regulation between KTI and TGF-␤ signaling pathways in human ovarian cancer cells, involving the upstream target(s) of Src. These findings identify anti-invasive properties of KTI at the level of tumor cells and may be relevant to the use of KTI in modulating cancer cell invasion and metastasis.
